

The growing dominance of ADCs in late-phase ovarian cancer trials

Market Trend Summary

ADC momentum builds in a crowded late-phase pipeline

- The ovarian cancer landscape is evolving quickly, with ADCs potentially becoming central to future treatment strategies.
- Mirvetuximab soravtansine is the only approved ADC, but several late-phase candidates are poised to expand the drug class.
- 2025 marked a turning point: 11 Phase 3 ovarian cancer trials evaluating ADCs were initiated, surpassing the 9 Phase 3 trials launched for all other drug classes.

Analysis of the ADC pipeline


12 new ADCs in late-phase development

6 different targets, including FRα, TROP2, and HER2


11 new Phase 3 trials evaluating ADCs initiated in 2025

67% of active Phase 3 trials focus on the platinum-resistant setting

New Phase 3 trials by year



Active ADC Phase 3 trials by population



Clarivate's takeaways

📍 Focus on platinum-resistant disease

ADCs remain highly focused on the platinum-resistant setting, where therapeutic options are limited and the unmet need is highest. However, several newly initiated studies are moving into earlier treatment lines, signaling a growing shift toward broader—and commercially lucrative—patient populations.

📈 Increasing market fragmentation and competition

The rapid expansion of late-phase ADCs will create a highly fragmented and competitive ovarian cancer landscape. As multiple agents advance through pivotal trials, clear differentiation—through target selection, payload design, safety profile, or clinical benefit—will be essential to secure meaningful market share.

❓ ADC sequencing remains a critical challenge

KOLs consistently highlight that treatment sequencing remains a major concern, driven by overlapping targets across ADCs and resistance mechanisms linked to shared payload technologies.

Ongoing late-phase clinical trials of ADCs in ovarian cancer

Antibody-drug conjugate	Target	Combination strategy	Phase 3 trial	Ovarian cancer setting	Primary Completion Date*
Mirvetuximab soravtansine (Elahere)	FR α	Bevacizumab	<u>GLORIOSA</u>	2L platinum-sensitive ovarian cancer (PSOC) maintenance	April 2027
Raludotatug deruxtecan	CDH6	Monotherapy	<u>REJOICE-Ovarian01</u>	2-5L platinum-resistant ovarian cancer (PROC)	February 2028
Rinatabart sesutecan	FR α	Monotherapy	<u>RAINFOL-02</u>	2-5L PROC	February 2027
		Bevacizumab	<u>RAINFOL-04</u>	2L platinum-sensitive maintenance	October 2028
Sacituzumab tirumotecan	TROP2	Bevacizumab	<u>TroFuse-022</u>	2L platinum-sensitive maintenance	April 2029
		Bevacizumab	<u>TroFuse-021</u>	1L maintenance	February 2033
Sofetabart mipitecan	FR α	Monotherapy or with bevacizumab	<u>FRAmework-01</u>	2-4L PROC and 2L platinum-sensitive maintenance	April 2028
Torvutatug samrotecan	FR α	Monotherapy	<u>TREVI-OC-01</u>	2-4L PROC	November 2028
Trastuzumab deruxtecan (Enhertu)	HER2	Bevacizumab	<u>DESTINY-Ovarian01</u>	1L maintenance	November 2028
SHR-A1921	TROP2	Monotherapy	<u>NCT06394492</u>	2L+ PROC	May 2026
		Carboplatin	<u>NCT06211023</u>	2L+ PSOC	June 2026
Trastuzumab rezetecan	HER2	Monotherapy	<u>NCT06828354</u>	2L+ PROC	December 2027
		Monotherapy	<u>NCT06990503</u>	2L+ PROC	June 2030
Izalontamab brengitecan	EGFR and HER3	Monotherapy	<u>NCT06994195</u>	2-4L PROC	June 2027
IBI-354	HER2	Monotherapy	<u>NCT06834672</u>	2L+ PROC	December 2027
JSKN003	HER2	Monotherapy	<u>NCT06751485</u>	2L+ PROC	December 2026
GSK-5733584	B7-H4	Monotherapy	<u>BEHOLD-Ovarian01</u>	2-5L PROC	January 2030
		Monotherapy	<u>NCT06855069</u>	2L+ PROC	March 2027

* Data extracted on March 18, 2026

About the author



Anna Duran, Ph.D.

Healthcare Research & Data Analyst

DRG Commercial Solutions

Prior to joining Clarivate, Dr. Duran was a postdoctoral fellow at IRB Barcelona, where she worked on the development of a new type of p38 α inhibitors with therapeutic potential. She holds a Ph.D. in biochemistry from the University of Barcelona and an M.Res. in chemical biology from Imperial College London.

Clarivate coverage of ovarian cancer

- Ovarian Cancer | [Disease Landscape & Forecast | G7](#)
- Ovarian Cancer | [Current Treatment: Physician Insights | US](#)
- Ovarian Cancer | [Current Treatment: Treatment Sequencing | US](#)



Think forward™

Have a question?

lsh.support@clarivate.com
clarivate.com

+1 215 386 0100 (U.S.)

+44 (0) 20 7433 4000 (Europe)

About Clarivate

Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com.

© 2026 Clarivate. All rights reserved

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.